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Abstract Galanin mediates diverse physiological functions in
digestive, endocrine, and central nervous systems through G-
protein-coupled receptors. Two galanin receptors have been
cloned but the gene structures are unknown. We report genomic
and cDNA cloning of the mouse GalR1 galanin receptor and
demonstrate that the coding sequence is uniquely divided into
three exons encoding the N-terminal portion through the fifth
transmebrane domain, the third intracellular loop, and the sixth
transmembrane domain through the C-terminus. Functional
analysis of the encoded cDNA revealed active ligand binding
and intracellular signaling. The expression is detected in brain,
spinal cord, heart and skeletal muscle.
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1. Introduction
Galanin is a widely distributed 29^30 amino acid peptide
involved in diverse regulatory e¡ects in many tissues [1,2].
Galanin modulates the release and secretion of many neuro-
transmitters and hormones in both the central nervous system
and peripheral tissues, such as acetylcholine, gastrin, insulin,
dopamine, growth hormone and prolactin. In peripheral tis-
sues, galanin inhibits insulin release by beta cells of the pan-
creas [3,4], as well as gastrin and somatostatin release from rat
stomach. In addition, intracerebraventrical injection of gala-
nin patently stimulates feeding in satiated animals [5,6].
The action of galanin is mediated through speci¢c recep-
tors. The receptor is a glycoprotein with an apparent molec-
ular weight of 54 kDa [7] and a signaling pathway is linked
through G-proteins to the inhibition of adenylyl cyclase
through a pertussis toxin-sensitive mechanism [8], as well as
to the modulation of other e¡ectors such as ATP-dependent
K

channel and Ca
2
channels. Physiological studies suggest
that the discovery of potent and speci¢c galanin receptor an-
tagonists may provide novel treatments for Alzheimer's dis-
ease [9,10] and morbid obesity [5,11]. Use of peptide agonists
and antagonists in pharmacological analysis suggests the ex-
istence of multiple galanin receptor subtypes [12^15] which
was con¢rmed by molecular cloning of human and rat
GalR1 [12^14] and rat GalR2 receptors [15,16]. These studies
revealed that the receptors are members of the G-protein-
coupled receptor (GPCR) superfamily, characterized by seven
hydrophobic transmembrane domains (TM) [17]. The human
GalR1 receptor has been mapped to chromosome 18q23 [18].
Despite the cDNA cloning of GalR1 and GalR2 receptors, the
genomic organizations of these genes have not been described.
In this report we describe the genomic and cDNA cloning,
exon/intron organization, and functional analysis of the
mouse galanin receptor.
2. Materials and methods
2.1. Materials
Rat [
125
I]galanin (2200 Ci/mmol) and K-[
32
P]dATP (5000 Ci/mmol)
were purchased from Du Pont-NEN (Boston, MA). Freshly frozen
mouse tissues (Swiss-Webster) were obtained from Pel-Freeze Biolog-
icals (Rogers, AR). Mouse multiple tissue Northern blots (MTN)
were obtained from Clontech (Palo Alto, CA, cat. #7762-1). Rat
galanin, rat galanin 1^16, M40, C7, and M35, and M15 were pur-
chased from Peninsula Laboratories (Belmont, CA). Rat galanins 2^
29 and 10^29 and oligonucleotides used in this study were custom-
synthesized by Bio-synthesis, Inc. (Lewisville, TX). Since rat and
mouse galanins are identical, rat [
125
I]galanin will be referred to as
mouse [
125
I]galanin, and rat galanin and peptides as mouse galanin
and peptides. Sequence determinations were performed with the £uo-
rescent dye termination method (Perkin Elmer, Branchburg, NJ) on
an automated DNA sequencer (Model 373, Applied Biosystems, Inc.).
Sequencing data were analyzed with DNA* software package (DNAs-
tar, Inc. Madison, WI).
2.2. Isolation of mouse galanin receptor genomic clones
The humanGalR1 cDNA, used as a probe to obtain mouse galanin
genomic clones, was obtained by reverse transcription-polymerase
chain reaction (RT-PCR) from total RNA of human melanoma cells
and cloned in vector pCRII (Invitrogen, San Diego, CA). The se-
quence was identical to the published sequence [12]. The full-length
human GalR1 cDNA was excised out of the pCRII vector by restric-
tion digestion and puri¢ed by agarose gel electrophoresis. The cDNA
was labeled with
32
P and used as probe to screen a mouse embryonic
stem cell (129SvEv stem embryonic cell) genomic library in bacterial
artifacial chromosomes (BAC) at high hybridization stringency (65³C)
(Genome System, Inc., St. Louis, MO). The BAC mouse GalR1 clones
were analyzed by restriction enzyme digestion and Southern blotting.
Fragments containing exonic sequences were subcloned into Blue-
script (ks-vector, Stratagene) for sequencing analysis.
2.3. Isolation of mouse GalR1 cDNA and tissue distribution
PCR primers were designed based on the nucleotide sequences in
the 5P and 3P untranslated regions of mouse GalR1 gene and used in
PCR to obtain mouse GalR1 cDNA. Total RNA of mouse brain was
extracted with the Tri Reagent kit (Molecular Research Center, Cin-
cinnati, OH). Poly A

RNA from the total RNA was puri¢ed with an
mRNA puri¢cation kit which employs oligo(dT)-cellulose chromatog-
raphy (Pharmacia, Piscataway, NJ). Double-stranded cDNA was syn-
thesized from the poly A

RNA with a Marathon cDNA ampli¢ca-
tion kit (Clontech). Mouse GalR1 cDNA was obtained by PCR with
the mouse brain cDNA as template (0.1 Wg) by using an Advantage
PCR kit (Clontech) for the ampli¢cation. The reaction (40 Wl) was
driven by the KlenTaq polymerase (5 U) in the presence of a forward
primer (oligo 57, 5P-tagccaggacaggcaggaggatagt-3P) and a reverse pri-
mer (oligo 58, 5P-gggaggctcccgcaaaccttcacac-3P) with a thermal cycling
pro¢le of 94³C for 1 min, 68³C for 1 min and 72³C for 1 min (40
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cycles) preceded with heating at 94³C for 5 min and followed by an
extension at 72³C for 7 min. Agarose gel analysis of the reaction
product showed a single band at the expected size of about 1.3 kb.
The PCR product (3 Wl) was ligated into a bi-directional TA cloning
vector, pCR3 (Invitrogen). For Northern blot analysis, mouse MTN
blots with 2 Wg poly A+ RNA in each lane were hybridized for 1.5 h
at 68³C in an ExpressHyb solution (Clontech) using
32
P-labeled full-
length mouse GalR1 cDNA as a probe (Random priming kit, Life
Technology, Gaithersburg, MD). After hybridization, the blots were
washed ¢rst with wash solution I (2U SSC, 0.05% SDS) for 10 min. at
room temperature then with wash solution II (0.1U SSC, 0.1% SDS)
for approximately 30 min at 45³C.
2.4. Transfection of COS-1 cells and [
125
I]galanin binding assay
COS-1 cells grown in Dulbecco's modi¢ed Eagle's medium
(DMEM) supplemented with 10% fetal calf serum (FCS) were split
1:6 into 150 mm dishes (Nunc) 3 days prior to transfection. Trans-
fection and membrane preparations were performed as previously
described [16]. Protein concentration was determined with the BCA
protein assay kit (Pierce, Rockford, IL) with bovine serum albumin
(BSA) (Sigma, St. Louis, MO) as standard. Binding of mouse
[
125
I]galanin to the mouse GalR1 receptor cells was performed in a
bu¡er containing 10 mM HEPES (pH 7.4), 0.05% BSA (RIA grade),
0.1% bacitracin, and 0.5 mM EDTA. Ligand saturation plots were
performed in triplicate with 2.5 Wg of the membrane protein in a total
volume of 50 Wl using 1 WM cold galanin to determine non-speci¢c
binding. Peptide competition studies were performed in duplicate in a
total volume of 200 Wl, containing 5 Wg of membrane protein and 0.1
nM [
125
I]galanin. Incubations were at room temperature for 1 h and
were terminated by rapid vacuum ¢ltration through Multiscreen FB
Filter Plates (Millipore, Bedford, MA) pretreated with 0.3% polyeth-
ylenimine. The ¢lters were then washed 3 times with 100 Wl of phos-
phate-bu¡ered saline (pH 7.4). All data were analyzed using non-lin-
ear regression software (Prism GraphPad, San Diego, CA) to ¢t one-
and two-site binding and the K
i
calculated according to the method of
Cheng and Pruso¡ [19].
2.5. Cyclic AMP analysis
COS-1 cells grown in 150 mm plates were transfected as described
above. After an overnight post-transfection growth, the cells were
trypsinized o¡ plates and subcultured into wells of 24 well plates at
a density of 2.5U10
5
cells/well and allowed to grow for 3 more days.
Cells were washed with PBS and incubated in DMEM for 1.5 h at
37³C then incubated in 1 ml of DMEM containing 0.1 mM forskolin,
0.2 mM 3-isobutyl-1-methylxanthine and mouse galanin at indicated
concentrations for 1 h at 37³C. The measurements were performed in
triplicate and intracellular cAMP was assayed with a [
3
H]cAMP de-
tection kit (Amersham, Arlington Heights, IL). The data were ana-
lyzed with the Prism non-linear regression program to obtain maxi-
mum inhibition and EC
50
values.
3. Results and discussion
3.1. Cloning and genomic organization of murine GalR1 gene
A murine genomic BAC library was screened with a
32
P-
labeled probe encoding the entire length of the human GalR1
cDNA under high stringency hybridization conditions. Two
positive clones with insert sizes v25 kb were obtained. Re-
striction enzyme digestion and Southern blot analysis indi-
cated that the two clones were identical; thus only one of
the clones was further analyzed by sub-cloning and sequenc-
ing. Fig. 1 shows the restriction map and Fig. 2 the genomic
sequence of the mouse GalR gene. An open reading frame
(ORF) of 1047 bp was identi¢ed and found to be disrupted
by two introns (Figs. 1A and 2A). The ¢rst intron, approx-
imately 3.4 kb in length, is located between nucleotides (nts)
663 and 664 (intron I) and the second, with a length of about
8.0 kb, between nts 729 and 730 (intron II) in the ORF. The
disruptions resulted in three separated exons in the ORF.
These exons, when translated to amino acid sequences, are
separated in frame and the resulting amino acid sequences
correspond to amino acids 1^221 (N-terminus to TM5, exon
I), amino acids 222^243 (third intracellular loop, exon II) and
amino acids 244^348 (TM6 to C-terminus, exon III) (Fig. 2).
The sequences of the two exon/intron junctions and the two
intron/exon junctions closely match the doner and acceptor
splice site consencus sequences, respectively [20]. Fig. 1B
shows the spliced transcript of the gene containing the puta-
tive start and stop codons.
The putative mouse GalR1 cDNA in the ORF consists of
1047 bp encoding a protein of 348 amino acids with a pre-
dicted molecular weight of 39.1 kDa. The receptor is highly
homologous to human [12] and rat [14] GalR1 receptors (91%
and 94%, respectively) and possesses only 39% homology to
rat GalR2 [15,16]. The most variable regions are the N- and
C-termini and the second extracellular loop. Comparison of
the mouse GalR1 amino acid sequence with other GPCRs and
a hydrophathy analysis [21] suggest that the protein contains
seven membrane spanning regions (TM) and an extracellular
N-terminus and a cytoplasmic C-terminus. Features conserved
in other members of the super family of GPCRs are also well
conserved in mouse GalR1 receptor. These include C108 and
C186, a pair of cysteine residues that may form a disul¢de
bond between extracellular loops 1 and 2 (E
1
and E
2
), two
consensus sites for N-linked glycosylation in the N-terminal
region, three serine residues for potential protein kinase C
phosphorylation, two potential cAMP/cGMP protein kinase
phosphorylation sites, and three C-terminal cysteine residues
that can serve as potential palmitoylation site (Fig. 2B). Ami-
no acid residues corresponding to H264, H267, F282 and
E271 in the human GalR1 receptor, which have been deter-
mined to be essential for the binding of galanin [22], are all
conserved (Fig. 2B).
3.2. Comparison of GalR1 gene with other GPCR genes
The structure of the mouse GalR1 gene is di¡erent from the
known genomic structures of other GPCRs. Most of these
receptors are intronless in the coding regions and only a small
number of them contain one or more introns in the coding
regions. Examples of single-intron genes are the neuropeptide
Y Y-1 receptor, with a small intron (V80^97 bp) inserted
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Fig. 1. Genomic organization of the mouse GalR1 receptor gene. A:
Restriction map of the gene. The line represents the gene with exons
(boxes) interrupted by introns (lines between boxes). Empty boxes
denote coding sequences and only the portions of exon I and exon
III within the coding region are shown. Restriction sites are: R,
EcoRI; B, BstXI; H, HindIII; and K, KpnI. The lengths of the re-
striction fragments are shown above the map. B: Detailed exon as-
signment within the coding region. The coding sequence is repre-
sented as one open box with the seven putative TMs shown as dark
boxes.
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after the ¢fth TM and before intracellular loop 3 (I
3
) [23,24].
The human K-1b-adrenergic receptor [25] and rat A
3
adeno-
sine receptor [26] also have a single intron located at the
proximal end of extracellular loop 4 (E
4
) and in the middle
of intracellular loop 2 (I
2
), respectively. The bombesin recep-
tor gene family contains two introns located in the central I
2
and I
3
regions, respectively [27]. The GPCR genes that possess
more than two introns, such as the endothelin B receptor
family with seven exons [28], opsin and rhodopsin receptor
family with ¢ve to six exons [29,30], the tachykinin receptor
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Fig. 2. The mouse GalR1 sequences. A: Nucleotide and deduced amino acid sequences. Nucleotide numbering starts with 1 at the translation
initiation site ATG. Nucleotides within introns 1 and 2 are not counted in the numbering system. Nucleotides in the coding region are shown
in upper case letters. Introns and non-coding sequences are shown in lower case letters. Only V20 nucleotides at each intron/exon junction are
shown. Amino acids constituting the predicted TMs and nucleotide sequences corresponding to the 5P (forward) and 3P (reverse) primers used
in cDNA cloning by RT-PCR are underlined. The underlined `taatata' denotes a putative polyadenylation signal. B: Alignment of the amino
acid sequences of mouse, human [12] and rat [13] GalR1 receptors. Amino acids in the human and rat receptors that are di¡erent from the
mouse are shown. Gaps (3) are introduced to optimize the alignment. Putative TMs are overlined and indicated by `TM' and Roman numer-
als. The potential glycosylation sites (

), phosphorylation sites (7) for cAMP/cGMP protein kinase, cysteine residues (b) presumed to form a
disul¢de bond, protein kinase C phosphorylation sites (#) and palmitoylation sites (O) are indicated above the mouse GalR 1 amino acid se-
quence.
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family with ¢ve exons [31,32], and the glucogan and GLP
receptor family with approximately 12 exons, all have one
single intron in I
3
regions. Since exons often encode functional
domains of proteins, the observation that I
3
of nearly all of
the intron-containing GPCR genes possesses a single intron is
consistent with the suggestion that I
3
and/or TM6 forms a
speci¢c domain which at least partly determines the speci¢city
of interaction with G-proteins. The genomic structure of the
mouse galanin receptor is di¡erent from above receptors in
that the two introns embrace exon II in-frame and are located
at the proximal and distal ends of loop I
3
(Fig. 2). Thus exon
II encodes 22 amino acids that span nearly the entire I
3
. This
region is highly basic, containing eight Lys and two His res-
idues, and a comparison of the sequence with proteins in the
data bank showed no appreciable homology of this region to
any other known protein. Thus, the splicing pattern of intron
I and intron II suggests that that the domain may have struc-
turally evolved by `exon-shu¥ing' [33] and this intracellular
loop may be functionally involved in signaling [34,35].
3.3. cDNA cloning and characterizaton of the murine GalR1
receptor
To determine whether the genomic clone encodes an active
galanin receptor, the cDNA was obtained by RT-PCR with
primers annealing to the 5P and 3P £anking regions of the
mouse genomic clone (forward primer [nt (3222)^(3246)]
and reverse primer (nt1044^1068), Fig. 2A) and total mouse
brain RNA as template. A PCR product of the expected size
of V1.3 kb was generated and cloned into the mammalian
expression vector pCR3. Sequencing of the mouse GalR1
cDNA revealed a sequence identical to that of the ORF iden-
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Fig. 2. (continued)
Fig. 3. Tissue distribution of mouse GalR1 mRNA by Northern
blot analysis. The graph shows one representative autoradiograph
produced by 1 week exposure of the ¢lter to Kodak BioMax ¢lm.
Lanes indicate poly A

RNA from mouse heart (lane A), brain
(lane B), spleen (lane C), lung (lane D), liver (lane E), skeletal
muscle (lane F), kidney (lane G) and testis (lane H), respectively.
The two small bars on the right indicate the size of the bands found
in brain (V9 kb) and skeletal muscle (V7 kb), respectively.
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ti¢ed in the genomic sequence (Fig. 2). No sequences from
either intron I or intron II were found.
Northern blot analysis and RT-PCR were performed to
determine mouse GalR1 expression in a number of tissues.
Full-length mouse GalR1 cDNA labeled with
3
P was hybrid-
ized to Northern blots containing poly A

RNA isolated from
di¡erent mouse tissues (Fig. 3). Mouse brain showed abun-
dant expression of GalR1, as evidenced by the presence of a
strong 9 kb mRNA band. Skeletal muscle and heart showed
moderate levels of expression of a 7^7.5 kb mRNA. No
mouse GalR1 mRNA was detected in liver, kidney, testis,
lung and spleen. The size di¡erences of the transcripts in
various tissues may result from heterogeneous processing of
the large 5P and 3P untranslated regions in di¡erent tissues.
RT-PCR analysis showed high levels of mouse GalR1 mRNA
in brain and spinal cord, and a somewhat reduced level of
expression in heart. No detectable signal was found in pitui-
tary, stomach, small intestine, liver, testis, ovaries, pancreas,
spleen, kidney and lung (not shown). The distribution is con-
sistent with the Northern blot analysis (Fig. 3 and [14]) and in
contrast to the wide tissue-distribution of GalR2 [16]. The
¢nding that skeletal muscle expresses the mouse GalR1 recep-
tor relatively abundantly suggests additional roles of galanin
in this tissue.
The ability of the receptor to bind galanin was examined by
the radioligand binding assay. Shown in Fig. 4A is the bind-
ing of mouse [
125
I]galanin to membranes prepared from trans-
fected COS-1 cells. Analysis of the data using non-linear re-
gression methods revealed a K
d
for mouse [
125
I]galanin of
0.134þ 0.014 nM and a B
max
of 767þ 20 fmol/mg protein.
The data were best ¢t to single-site model (r=0.996), suggest-
ing a single population of high-a¤nity receptors in these
membranes. Mouse [
125
I]galanin did not bind to COS-1 cell
membranes derived from cells transfected with vector pCR3
alone. The pharmacological properties of the mouse GalR1
receptor are shown in Fig. 4B. Mouse galanin has high a¤nity
for the mouse GalR1 receptor (K
i
=0.047 nM). Truncation of
the C-terminus of the peptide produced moderate reduction in
a¤nity for the receptor as shown with galanin1-16 (K
i
=1.02
nM). In contrast, deletion of the N-terminal amino acid Gly
markedly reduces the a¤nity (galanin 2^29, K
i
=84.6 nM),
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Fig. 4. Ligand binding of the mouse GalR1 receptor. A: Saturation
of mouse [
125
I]galanin binding to mouse GalR1 expressed in COS-1
cell membranes. Total (E), non-speci¢c (b) and speci¢c (F) binding
are shown as the average þSEM (n=3). The curves represent the
best ¢t to single-site binding isotherms. B: Competition for
[
125
I]galanin binding to COS-1 cell membranes containing the mouse
GalR1 receptor. The data are expressed as the percent of control
speci¢c binding (6659þ 187 cpm, meanþSEM, n=16). Non-speci¢c
binding was determined to be 128þ 8 cpm (meanþSEM, n=8). The
peptides assayed included galanin (F), galanin 1^16 (R), galanin 2^
29 (S), galanin 10^29 (8), M15 (P), M40 (E), C7 (O), and M35
(b).
Fig. 5. Inhibition of forskolin-stimulated cAMP production by
mouse galanin in COS-1 cells expressing the mouse GalR1 recceptor.
Transfected cells were incubated in the presence of 0.1 mM forsko-
lin alone (control) and mouse galanin at the indicated concentra-
tions. Results shown are meanþSD (n=3 wells). Error bars are
smaller than the size of the symbols when not shown. The curve in-
dicates the best ¢t to all the data points by one site non-linear re-
gression analysis. The basal and forskolin-stimulated cAMP produc-
tion levels were estimated at 5.0 þ 0.06 (n=3) and 59.0þ 1.2 (n=3)
pmol/10
6
cells, respectively.
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while removal of the ¢rst nine amino acids produces a peptide
that has no a¤nity for the galanin receptor (galanin 10^29).
Deletion of the Gly only resulted in slight loss of the a¤nity
to GalR2 [16]. The chimeric peptides M35, M40, C7 and M15
bound to the receptor with K
i
values of 0.067, 0.43, 0.96, and
2.24 nM, respectively. All of the peptides tested ¢t best to a
single class of sites using non-linear regression methods.
Mouse galanin caused a concentration-dependent inhibition
of forskolin-stimulated cAMP production in COS-1 cells ex-
pressing the mouse GalR1 receptor. Non-linear regression
analysis of the data gave a maximum inhibition of
67.0þ 2.4% and EC
50
of 0.19þ 0.07 nM (Fig. 5). Thus, the
cloned mouse receptor is functional in intracellular signaling
and activation of the receptor leads to an inhibition of for-
skolin-stimulated cAMP formation, presumably via interac-
tion with pertussis toxin-sensitive Gi/Go proteins.
In summary, we have isolated and characterized a gene
encoding an active mouse GalR1 receptor. The genomic or-
ganization of the mouse galanin receptor is unique among the
GPCRs. Of particular interest is the observation that exon II
encodes exclusively the third intracellular loop of the receptor,
suggesting the potential for di¡erential G-protein coupling by
exon shu¥ing within this functionally important region. Ex-
amples of inactive GPCRs that occurs only in certain species
have been observed, e.g. both mouse and human NPY PP2
receptors have been cloned, but only the mouse cDNA enc-
odes an active receptor [36]. The expressional analysis of the
mouse GalR1 receptor demonstrate that the mouse gene en-
codes an active receptor. The amino acid sequence, tissue
distribution, and pharmacological pro¢le of the receptor are
similar to those of other GalR1 receptors [12^14], but distinct
from those of GalR2 receptor [16]. Both receptors are linked
to inhibition of cAMP. The elucidation of the gene structure
should enhance our understanding of the gene regulation and
structure/function relationship of the GalR1 receptors. The
cloning and characterization of the mouse receptor should
aid in studies of galanin functions, such as feeding and cog-
nition, in mouse models.
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